Livongo Health Inc (LVGO) Has a New Rating from Chardan Capital

By Austin Angelo

In a report released today, Steven Wardell from Chardan Capital initiated coverage with a Hold rating on Livongo Health Inc (LVGOResearch Report) and a price target of $40. The company’s shares closed last Monday at $34.03.

Wardell wrote:

“We are initiating on Livongo (LVGO) with a Neutral rating and a 12-month Price Target of $40. Livongo Health (LVGO) is a provider of next-generation chronic care solutions through the employer and managed care channels. The company provides solutions to manage conditions such as diabetes, hypertension, prediabetes, and weight management, by means of smart connected devices and personalized digital guidance. Our channel checks find that Livongo is the market leader in next-generation diabetes solutions sold through the large employer channel and is well positioned to continue to sell into this large and growing market.”

According to TipRanks.com, Wardell is ranked #532 out of 5228 analysts.

The word on The Street in general, suggests a Hold analyst consensus rating for Livongo Health Inc.

See today’s analyst top recommended stocks >>

The company has a one-year high of $45.68 and a one-year low of $31.60. Currently, Livongo Health Inc has an average volume of 1.77M.

Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LVGO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.